Yunji (02670) proposes to appoint Wang Kegui as a candidate for non-executive director.

18:15 13/03/2026

Cloudtrack (02670) announced that the board of directors recommends appointing Mr. Wang Kegui as a candidate for non-executive director of the second session of the board of directors. His appointment will be subject to approval by the company's shareholders' meeting, and his directorship will be effective from the date of approval by the shareholders' meeting of the company until the expiration of the term of office of the second session of the board of directors.

YUNJI (02670) announced that the board of directors recommends appointing Mr. Wang Kegui as a candidate for non-executive director of the second board of directors of the company. His appointment will be finalized after approval by the company's shareholders' meeting, and his term as a director will be effective from the date of approval by the shareholders' meeting until the expiration of the term of the second board of directors.

Jiangsu Hengrui Pharmaceuticals' independently developed Class 1 innovative drug Haskubarparib ethylamine tablets approved for new indications.

YICHEN IND(01596) reports a profit increase, with an expected consolidated net profit of approximately 334 million yuan in 2025, a turnaround from a loss to a profit year-on-year.

On March 13th, BEISEN HOLDING (09669) spent 678,800 Hong Kong dollars to repurchase 150,000 shares.

Jiangsu Hengrui Pharmaceuticals' independently developed Class 1 innovative drug Haskubarparib ethylamine tablets approved for new indications.

YICHEN IND(01596) reports a profit increase, with an expected consolidated net profit of approximately 334 million yuan in 2025, a turnaround from a loss to a profit year-on-year.

On March 13th, BEISEN HOLDING (09669) spent 678,800 Hong Kong dollars to repurchase 150,000 shares.